HeartBeam, Inc. (NASDAQ: BEAT) reported first-quarter 2026 operational and financial results, highlighting the launch of its initial commercial partnerships in key U.S. markets, progress in its heart attack detection and ambulatory ECG patch initiatives, and an April public offering that raised $11.5 million in gross proceeds. The company posted a net loss of $4.7 million for the quarter, improved from $5.5 million in the prior-year period, with research and development expenses declining year over year as it advanced commercialization of its FDA-cleared cardiac monitoring platform.
The company's 3D ECG technology, which received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025, is designed as a cable-free device that collects ECG signals from three non-coplanar directions and synthesizes them into a 12-lead ECG. This platform is intended for portable use, enabling physicians to identify cardiac health trends and acute conditions outside of medical facilities. HeartBeam holds over 20 issued patents related to its technology.
The launch of commercial partnerships marks a significant step in bringing the HeartBeam system to patients and healthcare providers. The company's progress in heart attack detection and ambulatory ECG patch initiatives underscores its focus on comprehensive cardiac care. The $11.5 million public offering in April provides additional capital to support these growth initiatives and ongoing operations.
For more details, the full press release is available at https://ibn.fm/guMCF. Information about HeartBeam's cleared indications for use can be found at https://www.heartbeam.com/indications. The latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT.
